Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;165(1):3-21.
doi: 10.1111/imm.13420. Epub 2021 Oct 5.

Immunomodulatory functions of TRPM7 and its implications in autoimmune diseases

Affiliations
Free article
Review

Immunomodulatory functions of TRPM7 and its implications in autoimmune diseases

Hong-Yu Liang et al. Immunology. 2022 Jan.
Free article

Abstract

An autoimmune disease is an inappropriate response to one's tissues due to a break in immune tolerance and exposure to self-antigens. It often leads to structural and functional damage to organs and systemic disorders. To date, there are no effective interventions to prevent the progression of autoimmune diseases. Hence, there is an urgent need for new treatment targets. TRPM7 is an enzyme-coupled, transient receptor ion channel of the subfamily M that plays a vital role in pathologic and physiologic conditions. While TRPM7 is constitutively activated under certain conditions, it can regulate cell migration, polarization, proliferation and cytokine secretion. However, a growing body of evidence highlights the critical role of TRPM7 in autoimmune diseases, including rheumatoid arthritis, multiple sclerosis and diabetes. Herein, we present (a) a review of the channel kinase properties of TRPM7 and its pharmacological properties, (b) discuss the role of TRPM7 in immune cells (neutrophils, macrophages, lymphocytes and mast cells) and its upstream immunoreactive substances, and (c) highlight TRPM7 as a potential therapeutic target for autoimmune diseases.

Keywords: autoimmune disease; channel kinase; inflammation; rheumatoid arthritis; transient receptor potential melastatin 7.

PubMed Disclaimer

References

REFERENCES

    1. Gershwin LJ. Current and newly emerging autoimmune diseases. Vet Clin North Am Small Anim Pract. 2018;48:323-38.
    1. Coronel-Restrepo N, Posso-Osorio I, Naranjo-Escobar J, Tobon GJ. Autoimmune diseases and their relation with immunological, neurological and endocrinological axes. Autoimmun Rev. 2017;16:684-92.
    1. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278:369-95.
    1. Chandrashekara S. The treatment strategies of autoimmune disease may need a different approach from conventional protocol: a review. Indian J Pharmacol. 2012;6:65-71.
    1. van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, van Zeben D, Kerstens PJ, Gerards AH, et al. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis. 2007;66:1356-62.

Publication types

MeSH terms

LinkOut - more resources